Literature DB >> 28904199

Calcitonin Gene-Related Peptide Induces HIV-1 Proteasomal Degradation in Mucosal Langerhans Cells.

Morgane Bomsel1,2,3, Yonatan Ganor4,2,3.   

Abstract

The neuroimmune dialogue between peripheral neurons and Langerhans cells (LCs) within mucosal epithelia protects against incoming pathogens. LCs rapidly internalize human immunodeficiency virus type 1 (HIV-1) upon its sexual transmission and then trans-infect CD4+ T cells. We recently found that the neuropeptide calcitonin gene-related peptide (CGRP), secreted mucosally from peripheral neurons, inhibits LC-mediated HIV-1 trans-infection. In this study, we investigated the mechanism of CGRP-induced inhibition, focusing on HIV-1 degradation in LCs and its interplay with trans-infection. We first show that HIV-1 degradation occurs in endolysosomes in untreated LCs, and functionally blocking such degradation with lysosomotropic agents results in increased trans-infection. We demonstrate that CGRP acts via its cognate receptor and at a viral postentry step to induce faster HIV-1 degradation, but without affecting the kinetics of endolysosomal degradation. We reveal that unexpectedly, CGRP shifts HIV-1 degradation from endolysosomes toward the proteasome, providing the first evidence for functional HIV-1 proteasomal degradation in LCs. Such efficient proteasomal degradation significantly inhibits the first phase of trans-infection, and proteasomal, but not endolysosomal, inhibitors abrogate CGRP-induced inhibition. Together, our results establish that CGRP controls the HIV-1 degradation mode in LCs. The presence of endogenous CGRP within innervated mucosal tissues, especially during the sexual response, to which CGRP contributes, suggests that HIV-1 proteasomal degradation predominates in vivo Hence, proteasomal, rather than endolysosomal, HIV-1 degradation in LCs should be enhanced clinically to effectively restrict HIV-1 trans-infection.IMPORTANCE During sexual transmission, HIV-1 is internalized and degraded in LCs, the resident antigen-presenting cells in mucosal epithelia. Yet during trans-infection, infectious virions escaping degradation are transferred to CD4+ T cells, the principal HIV-1 targets. We previously found that the neuroimmune dialogue between LCs and peripheral neurons, innervating mucosal epithelia, significantly inhibits trans-infection via the action of the secreted neuropeptide CGRP on LCs. In this study, we investigated whether CGRP-induced inhibition of trans-infection is linked to CGRP-controlled HIV-1 degradation in LCs. We show that in untreated LCs, HIV-1 is functionally degraded in endolysosomes. In sharp contrast, we reveal that in CGRP-treated LCs, HIV-1 is diverted toward and degraded via another cytosolic protein degradative pathway, namely, the proteasome. These results establish that CGRP regulates HIV-1 degradation in LCs. As CGRP contributes to the sexual response and present within mucosal epithelia, HIV-1 proteasomal degradation in LCs might predominate in vivo and should be enhanced clinically.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Langerhans cells (LCs); calcitonin gene-related peptide (CGRP); degradation; human immunodeficiency virus type 1 (HIV-1); proteasome; trans-infection

Mesh:

Substances:

Year:  2017        PMID: 28904199      PMCID: PMC5686740          DOI: 10.1128/JVI.01205-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Optimization of HIV-1 infectivity assays.

Authors:  Jennifer Jones; William Whitford; Frederic Wagner; Olaf Kutsch
Journal:  Biotechniques       Date:  2007-11       Impact factor: 1.993

2.  Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1.

Authors:  O Schwartz; V Maréchal; B Friguet; F Arenzana-Seisdedos; J M Heard
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Calcitonin gene-related peptide inhibits human immunodeficiency type 1 transmission by Langerhans cells via an autocrine/paracrine feedback mechanism.

Authors:  Y Ganor; A-S Drillet-Dangeard; M Bomsel
Journal:  Acta Physiol (Oxf)       Date:  2014-09-11       Impact factor: 6.311

4.  Fluorescence-based proteasome activity profiling.

Authors:  Annemieke de Jong; Karianne G Schuurman; Boris Rodenko; Huib Ovaa; Celia R Berkers
Journal:  Methods Mol Biol       Date:  2012

5.  Within 1 h, HIV-1 uses viral synapses to enter efficiently the inner, but not outer, foreskin mucosa and engages Langerhans-T cell conjugates.

Authors:  Y Ganor; Z Zhou; D Tudor; A Schmitt; M-C Vacher-Lavenu; L Gibault; N Thiounn; J Tomasini; J-P Wolf; M Bomsel
Journal:  Mucosal Immunol       Date:  2010-06-23       Impact factor: 7.313

6.  Receptor usage dictates HIV-1 restriction by human TRIM5α in dendritic cell subsets.

Authors:  Carla M S Ribeiro; Ramin Sarrami-Forooshani; Laurentia C Setiawan; Esther M Zijlstra-Willems; John L van Hamme; Wikky Tigchelaar; Nicole N van der Wel; Neeltje A Kootstra; Sonja I Gringhuis; Teunis B H Geijtenbeek
Journal:  Nature       Date:  2016-12-07       Impact factor: 49.962

7.  MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors.

Authors:  Allan J Masterson; Claudia C Sombroek; Tanja D De Gruijl; Yvo M F Graus; Hans J J van der Vliet; Sinéad M Lougheed; Alfons J M van den Eertwegh; Herbert M Pinedo; Rik J Scheper
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

8.  Mutz-3-derived Langerhans cells are a model to study HIV-1 transmission and potential inhibitors.

Authors:  Marein A W P de Jong; Lot de Witte; Saskia J A M Santegoets; Donna Fluitsma; Maureen E Taylor; Tanja D de Gruijl; Teunis B H Geijtenbeek
Journal:  J Leukoc Biol       Date:  2009-12-30       Impact factor: 4.962

9.  HIV-1 efficient entry in inner foreskin is mediated by elevated CCL5/RANTES that recruits T cells and fuels conjugate formation with Langerhans cells.

Authors:  Zhicheng Zhou; Nicolas Barry de Longchamps; Alain Schmitt; Marc Zerbib; Marie-Cécile Vacher-Lavenu; Morgane Bomsel; Yonatan Ganor
Journal:  PLoS Pathog       Date:  2011-06-30       Impact factor: 6.823

10.  Caveolin-1 mediated uptake via langerin restricts HIV-1 infection in human Langerhans cells.

Authors:  Linda M van den Berg; Carla M S Ribeiro; Esther M Zijlstra-Willems; Lot de Witte; Donna Fluitsma; Wikky Tigchelaar; Vincent Everts; Teunis B H Geijtenbeek
Journal:  Retrovirology       Date:  2014-12-31       Impact factor: 4.602

View more
  5 in total

Review 1.  Innate Antiviral Immunity in the Skin.

Authors:  Chelsea Handfield; Jeffery Kwock; Amanda S MacLeod
Journal:  Trends Immunol       Date:  2018-03-08       Impact factor: 16.687

2.  CGRP inhibits human Langerhans cells infection with HSV by differentially modulating specific HSV-1 and HSV-2 entry mechanisms.

Authors:  Emmanuel Cohen; Jammy Mariotton; Flore Rozenberg; Anette Sams; Toin H van Kuppevelt; Nicolas Barry Delongchamps; Marc Zerbib; Morgane Bomsel; Yonatan Ganor
Journal:  Mucosal Immunol       Date:  2022-05-13       Impact factor: 8.701

3.  Structure and Dynamics of Adrenomedullin Receptors AM1 and AM2 Reveal Key Mechanisms in the Control of Receptor Phenotype by Receptor Activity-Modifying Proteins.

Authors:  Yi-Lynn Liang; Matthew J Belousoff; Madeleine M Fletcher; Xin Zhang; Maryam Khoshouei; Giuseppe Deganutti; Cassandra Koole; Sebastian G B Furness; Laurence J Miller; Debbie L Hay; Arthur Christopoulos; Christopher A Reynolds; Radostin Danev; Denise Wootten; Patrick M Sexton
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-20

Review 4.  Anti-migraine agents from an immunological point of view.

Authors:  Bakri M Assas
Journal:  J Transl Med       Date:  2021-01-06       Impact factor: 5.531

5.  Native CGRP Neuropeptide and Its Stable Analogue SAX, But Not CGRP Peptide Fragments, Inhibit Mucosal HIV-1 Transmission.

Authors:  Jammy Mariotton; Anette Sams; Emmanuel Cohen; Alexis Sennepin; Gabriel Siracusano; Francesca Sanvito; Lars Edvinsson; Nicolas Barry Delongchamps; Marc Zerbib; Lucia Lopalco; Morgane Bomsel; Yonatan Ganor
Journal:  Front Immunol       Date:  2021-12-08       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.